

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Lester F. Lau	Title:	CCN1 TRANSGENIC ANIMALS
App. No.:	10/774,706	Art Unit:	1638
Conf. No.:	2022	Examiner:	Popa, Ileana
Filing Date:	February 9, 2004		
Docket No:	05031.0008.NPUS01		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is submitted pursuant to 37 C.F.R. § 1.97(d) prior to payment of an issue fee under 37 C.F.R. § 1.97(d) but after the mailing date of a final action under 37 C.F.R. § 1.113. In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information contained in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The Commissioner is hereby authorized to deduct the fee of \$180 as set forth in 37 C.F.R. § 1.17(p) from Howrey, LLP Deposit Account 08-3038 referencing the above-identified docket number. No additional fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§1.16 to 1.21 be deemed necessary for any reasons relating to this document, the Commissioner is hereby authorized to deduct the fees from the above-identified Deposit Account.

Respectfully submitted,

HOWREY, LLP

By: /David W. Clough, Ph.D./
David W. Clough, Ph.D.
Registration No.: 36,107
Customer No.: 22930

January 19, 2007
HOWREY, LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60610
(312) 595-1239 (main)
(312) 595-1408 (direct)
(312) 595-2250 (fax)

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/774,706		
		Filing Date	February 9, 2004		
		First Named Inventor	Lester F. Lau		
		Art Unit	1638		
		Examiner Name	Popa, Ileana		
Sheet 1	1	of	1	Attorney Docket Number	05031.0008.NPUS01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C32	Collins, et al., "Use of Echocardiography for the Phenotypic Assessment of Genetically Altered Mice," Physiological Genomics, Vol. 13, pp. 227-239 (2003)	
	C33	Gui et al., "Doppler Echocardiography of Normal and Abnormal Embryonic Mouse Heart," Pediatric Research, Vol. 40, No. 4, pp. 633-642 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.